S&P 500   3,971.27 (-0.16%)
DOW   32,394.25 (-0.12%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
S&P 500   3,971.27 (-0.16%)
DOW   32,394.25 (-0.12%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
S&P 500   3,971.27 (-0.16%)
DOW   32,394.25 (-0.12%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
S&P 500   3,971.27 (-0.16%)
DOW   32,394.25 (-0.12%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
NASDAQ:NUVA

NuVasive - NUVA Stock Forecast, Price & News

$37.85
-0.18 (-0.47%)
(As of 03/28/2023 05:12 PM ET)
Add
Compare
Today's Range
$37.23
$38.56
50-Day Range
$36.81
$48.12
52-Week Range
$35.17
$60.47
Volume
650,976 shs
Average Volume
1.06 million shs
Market Capitalization
$1.98 billion
P/E Ratio
53.31
Dividend Yield
N/A
Price Target
$50.77

NuVasive MarketRank™ Forecast

Analyst Rating
Hold
2.18 Rating Score
Upside/​Downside
34.1% Upside
$50.77 Price Target
Short Interest
Bearish
9.91% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.29mentions of NuVasive in the last 14 days
Based on 9 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
18.81%
From $2.02 to $2.40 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.65 out of 5 stars

Medical Sector

93rd out of 1,002 stocks

Surgical & Medical Instruments Industry

7th out of 104 stocks


NUVA stock logo

About NuVasive (NASDAQ:NUVA) Stock

NuVasive, Inc. engages in the development, manufacture, sale, and provision of procedural solutions for spine surgery. It offers a comprehensive portfolio of procedurally integrated spine surgery solutions, including surgical access instruments, spinal implants, fixation systems, biologics, and enabling technologies, as well as systems and services for intraoperative neuromonitoring. The company was founded by Alexis V. Lukianov on July 21, 1997 and is headquartered in San Diego, CA.

Receive NUVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NuVasive and its competitors with MarketBeat's FREE daily newsletter.

NUVA Stock News Headlines

BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
NuVasive (NASDAQ:NUVA) Now Covered by Analysts at StockNews.com
NuVasive (NASDAQ:NUVA) Coverage Initiated at StockNews.com
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
NuVasive: Q4 Earnings Snapshot
NuVasive PT Raised to $53 at Barclays
NuVasive (NUVA) Q4 Earnings Miss Estimates, Margins Down
NuVasive (NUVA) Q4 Earnings and Revenues Miss Estimates
Globus Medical: Does The NuVasive Merger Make Sense?
Globus Medical to Buy NuVasive in $3.1 Billion Deal
See More Headlines
Receive NUVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NuVasive and its competitors with MarketBeat's FREE daily newsletter.

NUVA Company Calendar

Last Earnings
2/22/2023
Today
3/28/2023
Next Earnings (Estimated)
5/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:NUVA
CUSIP
67070410
Employees
3,000
Year Founded
1997

Price Target and Rating

Average Stock Price Forecast
$50.77
High Stock Price Forecast
$58.00
Low Stock Price Forecast
$44.50
Forecasted Upside/Downside
+32.8%
Consensus Rating
Hold
Rating Score (0-4)
2.18
Research Coverage
11 Analysts

Profitability

Net Income
$40.41 million
Pretax Margin
4.35%

Debt

Sales & Book Value

Annual Sales
$1.20 billion
Cash Flow
$5.12 per share
Book Value
$16.67 per share

Miscellaneous

Free Float
51,947,000
Market Cap
$2.00 billion
Optionable
Optionable
Beta
1.05

Social Links


Key Executives

  • J. Christopher BarryJ. Christopher Barry
    Chief Executive Officer & Director
  • Dale Wolf
    Senior Vice President-Global Operations
  • Matthew K. Harbaugh
    Chief Financial Officer & Executive Vice President
  • Kyle Malone
    Vice President-Scientific Affairs
  • Ryan Donahoe
    Chief Technology Officer & Senior Vice President













NUVA Stock - Frequently Asked Questions

Should I buy or sell NuVasive stock right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NuVasive in the last twelve months. There are currently 9 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" NUVA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NUVA, but not buy additional shares or sell existing shares.
View NUVA analyst ratings
or view top-rated stocks.

What is NuVasive's stock price forecast for 2023?

11 brokers have issued twelve-month target prices for NuVasive's stock. Their NUVA share price forecasts range from $44.50 to $58.00. On average, they anticipate the company's share price to reach $50.77 in the next year. This suggests a possible upside of 32.8% from the stock's current price.
View analysts price targets for NUVA
or view top-rated stocks among Wall Street analysts.

How have NUVA shares performed in 2023?

NuVasive's stock was trading at $41.24 at the beginning of the year. Since then, NUVA stock has decreased by 7.3% and is now trading at $38.24.
View the best growth stocks for 2023 here
.

When is NuVasive's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our NUVA earnings forecast
.

How were NuVasive's earnings last quarter?

NuVasive, Inc. (NASDAQ:NUVA) released its quarterly earnings results on Wednesday, February, 22nd. The medical device company reported $0.43 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.51 by $0.08. The medical device company earned $305.45 million during the quarter, compared to analyst estimates of $311.01 million. NuVasive had a trailing twelve-month return on equity of 12.45% and a net margin of 3.36%. The company's quarterly revenue was up 1.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.40 EPS.

How will NuVasive's stock buyback program work?

NuVasive announced that its Board of Directors has authorized a stock buyback program on Tuesday, November 9th 2021, which permits the company to repurchase $100,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization permits the company to reacquire up to 3.5% of its shares through open market purchases. Shares repurchase programs are often a sign that the company's leadership believes its shares are undervalued.

What guidance has NuVasive issued on next quarter's earnings?

NuVasive updated its FY 2023 earnings guidance on Wednesday, February, 22nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.27 billion-$1.30 billion, compared to the consensus revenue estimate of $1.28 billion.

What is Chris Barry's approval rating as NuVasive's CEO?

59 employees have rated NuVasive Chief Executive Officer Chris Barry on Glassdoor.com. Chris Barry has an approval rating of 88% among the company's employees.

What other stocks do shareholders of NuVasive own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NuVasive investors own include BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), Intel (INTC), Alibaba Group (BABA), (MDVN) (MDVN), Micron Technology (MU), Bank of America (BAC), Gilead Sciences (GILD) and Applied Materials (AMAT).

What is NuVasive's stock symbol?

NuVasive trades on the NASDAQ under the ticker symbol "NUVA."

Who are NuVasive's major shareholders?

NuVasive's stock is owned by a variety of institutional and retail investors. Top institutional investors include Thrivent Financial for Lutherans (6.18%), Dimensional Fund Advisors LP (2.78%), Paradice Investment Management LLC (2.67%), Geode Capital Management LLC (1.85%), Arrowstreet Capital Limited Partnership (1.58%) and Point72 Asset Management L.P. (1.57%). Insiders that own company stock include James Christopher Barry, Lucas Vitale, Massimo Calafiore and Matthew Link.
View institutional ownership trends
.

How do I buy shares of NuVasive?

Shares of NUVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NuVasive's stock price today?

One share of NUVA stock can currently be purchased for approximately $38.24.

How much money does NuVasive make?

NuVasive (NASDAQ:NUVA) has a market capitalization of $2.00 billion and generates $1.20 billion in revenue each year. The medical device company earns $40.41 million in net income (profit) each year or $0.71 on an earnings per share basis.

How many employees does NuVasive have?

The company employs 3,000 workers across the globe.

Does NuVasive have any subsidiaries?
The following companies are subsidiares of NuVasive: Biotronic NeuroNetwork, Ellipse Technologies, NuVasive Clinical Services Monitoring Inc., NuVasive Japan KK, NuVasive Specialized Orthopedics Inc., NuVasive Technology International Limited, SafePassage, Simplify Medical, and Vertera Spine.
Read More
How can I contact NuVasive?

NuVasive's mailing address is 7475 LUSK BOULEVARD, SAN DIEGO CA, 92121. The official website for the company is www.nuvasive.com. The medical device company can be reached via phone at (858) 909-1800, via email at investorrelations@nuvasive.com, or via fax at 800-475-9134.

This page (NASDAQ:NUVA) was last updated on 3/28/2023 by MarketBeat.com Staff